Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib
Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
The primary goal of this study is to gather efficacy data concerning the progression-free
survival rate with electromagnetic fields plus Regorafenib when compared to historical data
with Regorafenib alone as a second-line therapy in patients with advanced hepatocellular
carcinoma who have received any first line systemic therapy either standard of care Sorafenib
or Lenvatinib or any experimental therapy. Patients who have received any treatment that
includes either electromagnetic fields or Regorafenib will be excluded.